drugset / Trial / NCT02899702
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
RandomizedParallel-groupQuadruple-blindTreatment
Summary
IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.
Timeline
- Start
- 2020-09
- Primary completion
- 2024-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 2 g/kg | Intravenous |